Thera-SAbDab

ALEMTUZUMAB

>   Structural Summary
TherapeuticAlemtuzumab
TargetCD52
Heavy ChainQVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK
100% seqID Fv Structure1bey [Fvs: HL], 1ce1 [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '22)Approved
Estimated Status (Aug '22)Active
Recorded Developmental Technologyna
INN Year Proposed2000
INN Year Recommended2001
Companies InvolvedBayer HealthCare Pharmaceuticals Inc., Dana-Farber Cancer Institute, German CLL Study Group, Ohio State University Comprehensive Cancer Center, Sanofi, Sanofi Oncology, University of Cologne, University of Cambridge
Conditions ApprovedChronic lymphocytic leukaemia, Multiple sclerosis
Conditions ActiveLymphoma, T-cell prolymphocytic leukaemia
Conditions DiscontinuedRheumatoid arthritis, Diffuse large B cell lymphoma, Graft-versus-host disease, Sezary syndrome, T-cell lymphoma
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy